- Q3 2025 net income for BIOQUAL (BIOQ, Financial) surged to $936,030 from $275,026 in Q3 2024.
- Quarterly revenue fell 8.5% to $14.03 million compared to the same period last year.
- BIOQUAL reported a nine-month net loss of $951,497 against a profit of $1.66 million the previous year.
BIOQUAL, Inc. (OTC Pink: BIOQ) has unveiled its unaudited financial results for the third quarter of the fiscal year 2025. The company achieved a net income of $936,030, reflecting a notable increase from the $275,026 reported in the third quarter of 2024. Earnings per share also saw a rise to $1.05 from $0.31 year-over-year. However, BIOQUAL faced a decline in revenue, which fell to $14.03 million—a decrease of 8.5% from last year’s $15.34 million.
For the nine months ending February 28, 2025, BIOQUAL's revenue decreased by 20.5% to $37.20 million, down from $46.79 million in the comparable period of the previous year. The company experienced a net loss of $951,497, equivalent to a loss per share of $1.06. This is a reversal from the $1.66 million profit, or $1.86 per share, reported in the same nine-month span last year.
Despite the challenges in revenue, the significant rise in quarterly net income indicates improved profitability for BIOQUAL (BIOQ, Financial) in its third quarter. The company, based in Rockville, Maryland, specializes in diagnostics and research within the healthcare sector and continues to navigate the financial landscape with strategic adjustments.
